Study of Molecular Response Adaptive Immuno-Chemotherpay in Patients With NSCLC

Condition:   Non-Small Cell Lung Cancer Intervention:   Drug: Pembrolizumab Sponsors:   Canadian Cancer Trials Group;   Cancer Research Institute, New York City;   Personal Genome Diagnostics (PGDx);   Mark Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials